Mode
Text Size
Log in / Sign up

Concurrent osteosarcoma can be masked by brown tumors in patients with primary hyperparathyroidismRare bone cancer hidden by hyperparathyroidism in elderly patient

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that extensive bone destruction disproportionate to PTH levels may mask concurrent malignancy like osteosarcoma.

This report and literature review describes a rare clinical scenario where primary hyperparathyroidism (PHPT) masked an underlying malignancy. A 65-year-old female presented with a left hip lesion that initially appeared to be a brown tumor caused by PHPT. However, a second pathology examination confirmed the presence of concurrent osteosarcoma.

The authors highlight the risk of misdiagnosis when reactive features of hyperparathyroidism mimic malignant processes. They argue that clinicians must remain vigilant for red flags, specifically solitary or extensive bone destruction that is disproportionate to the patient's PTH levels. In such cases, expanded sampling and multimodal imaging are recommended to rule out malignancy.

A primary limitation of this evidence is the small sample size consisting of only 1 case report. The findings are based on a single occurrence where masking occurred. Clinical application suggests that while rare, concurrent malignancies in patients with metabolic bone conditions require careful diagnostic scrutiny.

How this fits prior evidence

This case report addresses a gap in clinical recognition regarding the differentiation between benign and malignant bone lesions in patients with hyperparathyroidism. It does not directly relate to previously covered topics such as targeted cytokine delivery platforms in canine oncology, natural products for osteosarcoma development, or immunotherapy and metabolic-targeted drug combinations for osteosarcoma treatment.

Imagine having a painful bone issue that looks like one condition, only to find out it is something much more serious. In this case, a 65-year-old woman had a lesion in her left hip. Because she had primary hyperparathyroidism (a condition where the parathyroid glands are overactive), doctors initially thought the growth was just a common brown tumor caused by her hormone levels.

However, a second look at the tissue revealed a different reality. The patient actually had osteosarcoma, which is a type of bone cancer. This case shows how easily one condition can hide another. Because both conditions can cause bone damage, it can be hard for doctors to tell them apart just by looking at initial tests.

This story highlights why extra caution is needed. Doctors are advised to look for red flags, such as a single area of large bone destruction that seems too big for the patient's hormone levels. In cases like this, more imaging and extra tissue samples can help ensure a hidden cancer is not missed.

What this means for you:
A rare bone cancer can sometimes be mistaken for a common condition caused by high parathyroid hormones.

Common questions

What is osteosarcoma?

Osteosarcoma is a type of cancer that forms in the bone. In this specific case, it was found in the hip of a 65-year-old woman. It can sometimes look like other types of bone damage, making it difficult to identify without careful examination.

How did the patient's condition affect her diagnosis?

The patient had primary hyperparathyroidism, which caused her hip lesion to look like a common brown tumor. Because both conditions can damage bone, the cancer was only identified during a second pathology examination of the tissue.

What should doctors look for in similar cases?

Doctors are advised to watch for red flags, such as a single area of extensive bone destruction that is not proportional to the patient's hormone levels. When these signs appear, they may need more imaging and extra tissue samples.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
The coexistence of primary osteosarcoma in the setting of primary hyperparathyroidism (PHPT) is exceedingly rare, and overlapping features between reactive brown tumors and malignancies pose a severe risk of misdiagnosis and diagnostic omission. We report the case of a 65-year-old female who presented with a left hip lesion. Although her clinical manifestations, imaging features, and initial pathology all favored a PHPT-induced brown tumor, a second pathology examination confirmed the coexistence of osteosarcoma within the pelvic lesion. In patients with PHPT, reactive giant cell hyperplasia and cystic degeneration can easily mask the malignant components of osteosarcoma. When encountering “red flags”, such as a solitary, extensive bone destruction that is disproportionate to parathyroid hormone (PTH) levels, clinicians must remain vigilant for a concurrent malignant bone tumor and promptly perform expanded sampling to prevent missed diagnoses. Multimodal imaging evaluations and, when necessary, repeated or expanded biopsies are also critical to avoiding misdiagnosis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.